Coram, Inc.

Client Profile
Coram Healthcare Corporation, (“Corma” or the “Company”), a publicly-traded company, is the country’s largest provider of home infusion therapy products and services with revenue in excess of $400 million.
After two plans of reorganization were rejected by the Bankruptcy Court, SSG was retained to provide various valuation services and to facilitate the Company’s emergence from bankruptcy through a sale or restructuring.
To date, valuation services have included: enterprise valuation for the purposes of calculating the impairment of goodwill in order to comply with FAS 142; valuation to calculate the exchange of Senior Notes to Series B; preferred stock in order for the Debtor to comply with the regulatory requirements of Stark II; preferred stock valuation. SSG also provided expert testimony in Bankruptcy Court related to the aforementioned valuations.

(610) 940-1094Email
New York
(212) 786-7432Email